Carsten F.
- Country
- Germany
- Department
- Ophthalmology
Research Overview
- Phase 2 Double-Masked Placebo-Controlled Dose-Finding Study of Danicopan in Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
- Phase 3 Open-Label Extension Study on the Safety of Intravitreal Avacincaptad Pegol in Geographic Atrophy Patients Post-GATHER2 Completion
Data & Insights
Has run more than one trial at 52 of 112 partner sites.
Specializations
Ophthalmic Disorders
The investigator specializes in treating advanced eye conditions, with particular emphasis on Geographic Atrophy (GA) and its relationship to Age-related Macular Degeneration (AMD).
- Macular Degeneration Management
- Retinal Disease Treatment
- Vision Loss Prevention
Therapeutic Approaches
Focus on innovative treatment methodologies including intravitreal administration of novel therapeutic agents and evaluation of emerging gene therapy approaches for retinal conditions.
- Advanced Drug Delivery Systems
- Novel Therapeutic Compounds
- Long-term Treatment Strategies
Clinical Expertise
Specialized in monitoring disease progression and evaluating therapeutic responses in patients with advanced retinal conditions, particularly focusing on GA lesion growth assessment.
- Treatment Safety Evaluation
- Disease Monitoring
- Clinical Outcomes Assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.